Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 64 articles:
HTML format
Text format



Single Articles


    March 2017
  1. FALLOWFIELD L, Solis-Trapala I, Menon U, Langridge C, et al
    The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  2. SHATHASIVAM P, Kollara A, Spybey T, Park S, et al
    VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    February 2017
  3. KIM SJ, Rosen B, Fan I, Ivanova A, et al
    Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  4. LINDEMANN K, Gibbs E, Avall-Lundqvist E, dePont Christensen R, et al
    Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).
    Br J Cancer. 2017 Jan 24. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  5. KAR SP, Adler E, Tyrer J, Hazelett D, et al
    Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    December 2016
  6. KOMMOSS S, Kommoss F, Diebold J, Lax S, et al
    Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review.
    Br J Cancer. 2016 Dec 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  7. COOK LS, Pestak CR, Leung AC, Steed H, et al
    Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  8. LICAJ I, Jacobsen BK, Selmer RM, Maskarinec G, et al
    Smoking and risk of ovarian cancer by histological subtypes: an analysis among 300 000 Norwegian women.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    November 2016
  9. LI X, Chen W, Zeng W, Wan C, et al
    microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  10. LEDERMANN JA, Harter P, Gourley C, Friedlander M, et al
    Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
    Br J Cancer. 2016 Nov 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  11. ZAAIJER LH, van Doorn HC, Mourits MJ, van Beurden M, et al
    Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2016 Oct 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  12. KONECNY GE, Kristeleit RS
    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
    Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  13. SHAFRIR AL, Babic A, Tamimi RM, Rosner BA, et al
    Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    September 2016
  14. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  15. DONAT-VARGAS C, Akesson A, Berglund M, Glynn A, et al
    Dietary exposure to polychlorinated biphenyls and risk of breast, endometrial and ovarian cancer in a prospective cohort.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  16. QIN B, Moorman PG, Alberg AJ, Barnholtz-Sloan JS, et al
    Dairy, calcium, vitamin D and ovarian cancer risk in African-American women.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  17. YANG Z, Wang XL, Bai R, Liu WY, et al
    miR-23a promotes IKKalpha expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  18. FRUSCIO R, Ceppi L, Corso S, Galli F, et al
    Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  19. BRONGER H, Singer J, Windmuller C, Reuning U, et al
    CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.
    Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  20. SAYASNEH A, Ferrara L, De Cock B, Saso S, et al
    Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study.
    Br J Cancer. 2016 Aug 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    July 2016
  21. VAIDYANATHAN A, Sawers L, Gannon AL, Chakravarty P, et al
    ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
    Br J Cancer. 2016 Jul 14. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    June 2016
  22. CANNIOTO RA, LaMonte MJ, Kelemen LE, Risch HA, et al
    Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium.
    Br J Cancer. 2016 Jun 14. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  23. WANG C, Winterhoff BJ, Kalli KR, Block MS, et al
    Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer.
    Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    March 2016
  24. BROWN JS, Kaye SB, Yap TA
    PARP inhibitors: the race is on.
    Br J Cancer. 2016;114:713-5.
    PubMed     Text format    


  25. RATNER ES, Zhu YL, Penketh PG, Berenblum J, et al
    Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
    Br J Cancer. 2016;114:777-86.
    PubMed     Text format     Abstract available


  26. DREW Y, Ledermann J, Hall G, Rea D, et al
    Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Br J Cancer. 2016 Mar 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    February 2016
  27. PERES LC, Camacho F, Abbott SE, Alberg AJ, et al
    Analgesic medication use and risk of epithelial ovarian cancer in African American women.
    Br J Cancer. 2016 Feb 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  28. HIRAMATSU K, Yoshino K, Serada S, Yoshihara K, et al
    Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas.
    Br J Cancer. 2016;114.
    PubMed     Text format     Abstract available


  29. HARRINGTON BS, He Y, Davies CM, Wallace SJ, et al
    Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
    Br J Cancer. 2016;114:417-26.
    PubMed     Text format     Abstract available


    January 2016
  30. SIVALINGAM VN, Kitson S, McVey R, Roberts C, et al
    Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
    Br J Cancer. 2016 Jan 21. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  31. TRILLSCH F, Kuerti S, Eulenburg C, Burandt E, et al
    E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer.
    Br J Cancer. 2016 Jan 12. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    December 2015
  32. KOTI M, Siu A, Clement I, Bidarimath M, et al
    A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Br J Cancer. 2015;113:1746.
    PubMed     Text format    


  33. DREW Y
    The development of PARP inhibitors in ovarian cancer: from bench to bedside.
    Br J Cancer. 2015;113.
    PubMed     Text format     Abstract available


  34. GEORGE A
    UK BRCA mutation testing in patients with ovarian cancer.
    Br J Cancer. 2015;113.
    PubMed     Text format     Abstract available


  35. LEDERMANN JA, El-Khouly F
    PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.
    Br J Cancer. 2015;113.
    PubMed     Text format     Abstract available


  36. CIBULA D, Balmana J
    PARP inhibitors in ovarian cancer.
    Br J Cancer. 2015;113.
    PubMed     Text format    


  37. MURRAY MJ, Bell E, Raby KL, Rijlaarsdam MA, et al
    A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
    Br J Cancer. 2015 Dec 15. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  38. KUMAR J, Fraser FW, Riley C, Ahmed N, et al
    Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.
    Br J Cancer. 2015;113:1642-3.
    PubMed     Text format    


    November 2015
  39. BESEVIC J, Gunter MJ, Fortner RT, Tsilidis KK, et al
    Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study.
    Br J Cancer. 2015 Nov 10. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  40. IKEDA Y, Oda K, Ishihara H, Wada-Hiraike O, et al
    Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.
    Br J Cancer. 2015 Nov 10. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    October 2015
  41. GERSHENSON DM, Sun CC, Wong KK
    Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.
    Br J Cancer. 2015 Oct 20. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    September 2015
  42. MENG X, Joosse SA, Muller V, Trillsch F, et al
    Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients.
    Br J Cancer. 2015 Sep 22. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  43. KERKLAAN BM, Lolkema MP, Devriese LA, Voest EE, et al
    Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.
    Br J Cancer. 2015;113:706-15.
    PubMed     Text format     Abstract available


  44. HASHIBE M, Galeone C, Buys SS, Gren L, et al
    Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort.
    Br J Cancer. 2015;113:809-16.
    PubMed     Text format     Abstract available


    July 2015
  45. VAN DER NOLL R, Marchetti S, Steeghs N, Beijnen JH, et al
    Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
    Br J Cancer. 2015 Jul 16. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  46. HSU KF, Shen MR, Huang YF, Cheng YM, et al
    Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer.
    Br J Cancer. 2015 Jul 9. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  47. NAGLE CM, Dixon SC, Jensen A, Kjaer SK, et al
    Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.
    Br J Cancer. 2015 Jul 7. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    April 2015
  48. MIZUNO M, Kajiyama H, Shibata K, Mizuno K, et al
    Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.
    Br J Cancer. 2015;112:1376-83.
    PubMed     Text format     Abstract available


    March 2015
  49. ABIKO K, Matsumura N, Hamanishi J, Horikawa N, et al
    IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
    Br J Cancer. 2015 Mar 31. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  50. MCPHAIL S, Johnson S, Greenberg D, Peake M, et al
    Stage at diagnosis and early mortality from cancer in England.
    Br J Cancer. 2015;112 Suppl 1:S108-15.
    PubMed     Text format     Abstract available


  51. LI K, Husing A, Fortner RT, Tjonneland A, et al
    An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study.
    Br J Cancer. 2015 Mar 5. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    January 2015
  52. MIYAMOTO M, Takano M, Iwaya K, Shinomiya N, et al
    High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.
    Br J Cancer. 2015 Jan 27. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  53. TRILLSCH F, Mahner S, Vettorazzi E, Woelber L, et al
    Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study.
    Br J Cancer. 2015 Jan 6. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  54. KOTI M, Siu A, Clement I, Bidarimath M, et al
    A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Br J Cancer. 2015;112 Suppl:1215-22.
    PubMed     Text format     Abstract available


    December 2014
  55. CEBULLA J, Huuse EM, Pettersen K, van der Veen A, et al
    MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.
    Br J Cancer. 2014 Dec 23. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  56. CARLUCCI A, D'Angiolella V
    It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.
    Br J Cancer. 2014 Dec 9. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  57. ANSALONI L, Coccolini F, Morosi L, Ballerini A, et al
    Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.
    Br J Cancer. 2014 Dec 2. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    November 2014
  58. BAANDRUP L, Dehlendorff C, Friis S, Olsen JH, et al
    Statin use and risk for ovarian cancer: a Danish nationwide case-control study.
    Br J Cancer. 2014 Nov 13. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  59. OSE J, Fortner RT, Schock H, Peeters PH, et al
    Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort.
    Br J Cancer. 2014 Nov 4. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    October 2014
  60. KOBEL M, Madore J, Ramus SJ, Clarke BA, et al
    Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
    Br J Cancer. 2014 Oct 30. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  61. JI J, Sundquist J, Sundquist K
    Lactose intolerance and risk of lung, breast and ovarian cancers: aetiological clues from a population-based study in Sweden.
    Br J Cancer. 2014 Oct 14. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    July 2014
  62. SAWERS L, Ferguson MJ, Ihrig BR, Young HC, et al
    Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.
    Br J Cancer. 2014 Jul 10. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    April 2014
  63. BENDIFALLAH S, Darai E
    Response to 'Comment on external multicentre validation of a nomogram predicting the risk of relapse in patients with borderline ovarian tumours'
    Br J Cancer. 2014 Apr 22. doi: 10.1038/bjc.2014.
    PubMed     Text format    


    January 2014
  64. OBERMAIR A
    Reply: comment on 'External multicentre validation of a nomogram predicting the risk of relapse in patients with borderline ovarian tumours'
    Br J Cancer. 2014 Jan 21. doi: 10.1038/bjc.2014.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: